News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
758,634 Results
Type
Article (74955)
Company Profile (418)
Press Release (683261)
Section
Business (213664)
Career Advice (3083)
Deals (36978)
Drug Delivery (114)
Drug Development (87781)
Employer Resources (173)
FDA (17727)
Job Trends (16064)
News (368047)
Policy (37129)
Tag
Academia (2920)
Alliances (54476)
Alzheimer's disease (1336)
Approvals (17635)
Artificial intelligence (153)
Bankruptcy (369)
Best Places to Work (12086)
Biotechnology (291)
Breast cancer (129)
Cancer (1173)
Cardiovascular disease (109)
Career advice (2601)
Cell therapy (270)
Clinical research (69218)
Collaboration (417)
Compensation (192)
COVID-19 (2777)
C-suite (104)
Data (1154)
Diabetes (166)
Diagnostics (6433)
Drug pricing (101)
Earnings (83601)
Employer resources (153)
Events (113439)
Executive appointments (325)
FDA (18292)
Funding (378)
Gene therapy (200)
GLP-1 (690)
Government (4766)
Healthcare (19845)
Infectious disease (2869)
Inflammatory bowel disease (121)
Interviews (574)
IPO (16822)
Job creations (4388)
Job search strategy (2174)
Layoffs (472)
Legal (8924)
Lung cancer (189)
Manufacturing (200)
Medical device (13846)
Medtech (13851)
Mergers & acquisitions (20228)
Metabolic disorders (470)
Neuroscience (1641)
NextGen Class of 2024 (7162)
Non-profit (4906)
Northern California (1495)
Obesity (270)
Opinion (242)
Patents (112)
People (60179)
Phase I (21353)
Phase II (30134)
Phase III (22752)
Pipeline (470)
Postmarket research (3300)
Preclinical (9604)
Radiopharmaceuticals (258)
Rare diseases (244)
Real estate (6580)
Regulatory (24869)
Research institute (2623)
Resumes & cover letters (487)
Southern California (1324)
Startups (3982)
United States (14065)
Vaccines (639)
Weight loss (219)
Date
Today (1)
Last 7 days (695)
Last 30 days (3696)
Last 365 days (37599)
2024 (34530)
2023 (41860)
2022 (53143)
2021 (57722)
2020 (56425)
2019 (49738)
2018 (37814)
2017 (35708)
2016 (35769)
2015 (41702)
2014 (35537)
2013 (31923)
2012 (33267)
2011 (33517)
2010 (32568)
Location
Africa (1099)
Arizona (176)
Asia (46065)
Australia (7962)
California (3420)
Canada (1306)
China (266)
Colorado (154)
Connecticut (165)
Europe (104226)
Florida (473)
Georgia (118)
Illinois (379)
Indiana (204)
Kansas (101)
Maryland (618)
Massachusetts (2733)
Michigan (175)
Minnesota (284)
New Jersey (980)
New York (991)
North Carolina (798)
Northern California (1495)
Ohio (146)
Pennsylvania (840)
South America (1424)
Southern California (1324)
Texas (480)
Washington State (385)
758,634 Results for "centre for drug research and development".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
Algernon Pharmaceuticals Inc. is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), along with the Centre for Human Drug Research (CHDR), will present its Phase 1 stroke study data at the Interdisciplinary Conference on Psychedelic Research being held June 6-8, 2024.
April 24, 2024
·
7 min read
Drug Development
Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies
Aleta Biotherapeutics, a clinical stage, immuno-oncology company with a CAR T-Cell Engager platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, announce the first patient was dosed in a Phase 1/2 clinical trial.
February 21, 2024
·
5 min read
Business
Macomics and the Institute of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Collaboration in Prostate Cancer Drug Development
Macomics Ltd, a leader in macrophage drug discovery, announces that it has entered a scientific collaboration with Prof. Andrea Alimonti at IOR, one of Switzerland’s leading research institutes.
June 19, 2024
·
5 min read
Business
Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002
Gabather AB (Nasdaq First North Growth Market: GABA) announces that the Company has signed a Collaborative Agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia.
April 10, 2024
·
5 min read
BioMidwest
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
Critical Path Institute and Centogene N.V. are pleased to announce the signing of a Memorandum of Understanding to advance drug development for lysosomal diseases and improve the quality of life for those impacted by these conditions.
June 20, 2024
·
5 min read
Business
ImmunoScape Partners with Singapore’s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics
ImmunoScape Partners with Singapore’s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics.
December 21, 2023
·
3 min read
Press Releases
Oxford-Harrington Rare Disease Centre to Host Symposium on Pioneering Research and Innovation in Rare Disease Treatments
September 24, 2024
·
4 min read
Adcomms
AstraZeneca Fends Off Adcomm’s Safety Concerns on Andexxa, Axes Mid-Stage Opioid Use Disorder Drug
The pharma is seeking full approval for its anticoagulation reversal drug Andexxa, which the FDA granted accelerated approval in 2018 for patients who had been treated with apixaban or rivaroxaban.
November 22, 2024
·
3 min read
·
Tristan Manalac
BioCapital
NIH researchers develop AI tool with potential to more precisely match cancer drugs to patients
In a proof-of-concept study, researchers at the National Institutes of Health have developed an artificial intelligence tool that uses data from individual cells inside tumors to predict whether a person’s cancer will respond to a specific drug.
April 18, 2024
·
4 min read
Press Releases
Citryll and leading rheumatology centres receive Reumanederland grant to collaborate on NET research to advance novel treatments for rheumatoid arthritis.
October 3, 2024
·
3 min read
1 of 75,864
Next
